<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60692">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315833</url>
  </required_header>
  <id_info>
    <org_study_id>AC-MIGPREV-1</org_study_id>
    <nct_id>NCT02315833</nct_id>
  </id_info>
  <brief_title>The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients</brief_title>
  <official_title>The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients. Randomized Intervention Trial With a Medical Device (Acetium®Capsules)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohit Oyj</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Finnish Funding Agency for Technology and Innovation (TEKES)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biohit Oyj</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to validate the novel hypothesis that daily use of L-cysteine
      (Acetium® capsules) is an effective means to decrease the frequency of (or completely abort)
      the headache attacks in migraine patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of migraine attacks (NMA) per evaluation interval</measure>
    <time_frame>3 months</time_frame>
    <description>The frequency of headache attacks during the entire treatment period (3 months) is compared with the baseline frequencies, to disclose the differences in efficacy measures between the two arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of migraine days (NMD) per evaluation period</measure>
    <time_frame>3 months</time_frame>
    <description>The frequency of headache days during the entire treatment period (3 months) is compared with the baseline frequencies, to disclose the differences in efficacy measures between the two arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Acetium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will administer Acetium capsules (100mg l-cysteine) twice a day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will administer placebo capsules twice a day for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetium</intervention_name>
    <description>Capsule for oral administration contains L-cysteine 100mg</description>
    <arm_group_label>Acetium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo capsule matching Acetium for oral administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years male/female

          -  subjects should report migraine attacks with the frequency of 2-8 times per month,
             and with less than 15 migraine days (NMD) per month. To be calculated as a separate
             attack, there should be at least 48h of freedom from headache between the two attacks
             of migraine.

          -  migraine with or without aura has been present for at least 1 year prior to entering
             into the study

          -  subjects to be enrolled should report the onset of their migraine before 50 years of
             age

        Exclusion Criteria:

          -  patients who meet the International Classification of Headache Disorders II criteria
             for medication overuse

          -  patients who have taken anti-psychotics or anti-depressant medications during the
             previous 3 months

          -  patients who abuse alcohol or other drugs

          -  patients resistant to all acute migraine drugs optimally prescribed

          -  potentially fertile and sexually active women who do not practise contraception

          -  other acute or chronic pain disorders

          -  severe psychiatric disease

          -  infection

          -  malignancy

          -  short life expectancy

          -  cardiovascular disease

          -  cerebrovascular disease

          -  uncontrolled hypertension

          -  degenerative central nervous system diseases

          -  pregnant and lactating women

          -  regular users of Acetium capsules for other indications

          -  persons suffering from renal dysfunction or cystinuria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kari Syrjänen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Biohit Oyj</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikko Kallela, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsingin Päänsärkykeskus Oy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lääkärikeskus Aava, Helsingin Päänsärkykeskus Oy</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikko Kallela, MD, PhD</last_name>
      <phone>0035850 5910702</phone>
      <email>mikko.kallela@pp.fimnet.fi</email>
    </contact>
    <contact_backup>
      <last_name>Anne Nyrhinen</last_name>
      <phone>0035850 5910702</phone>
      <email>anne.nyrhinen@aava.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Mikko Kallela, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Färkkilä, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terveystalo, Kamppi</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Keski-Säntti, MD, PhD</last_name>
      <phone>00358503738938</phone>
      <email>petra.keski-santti@terveystalo.com</email>
    </contact>
    <investigator>
      <last_name>Petra Keski-Säntti, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terveystalo, Jyväskylä</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matti Ilmavirta, MD, PhD</last_name>
      <phone>0035850-5631802</phone>
      <email>Matti.ilmavirta@terveystalo.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna Kinnunen</last_name>
      <phone>0035850-5631802</phone>
      <email>Anna.Kinnunen@terveystalo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Matti Ilmavirta, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terveystalo, Oulu</name>
      <address>
        <city>Oulu</city>
        <zip>90101</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikko Kärppä, MD, PhD</last_name>
      <phone>0035810 345 2931</phone>
      <email>mikko.karppa@oulu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Jaana Vainionpää</last_name>
      <phone>0035810 345 2931</phone>
      <email>jaana.vainionpaa@terveystalo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mikko Kärppä, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terveystalo, Turku</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markku Nissilä, MD</last_name>
      <phone>00358400 788 020</phone>
      <email>markku.nissila@terveystalo.com</email>
    </contact>
    <contact_backup>
      <last_name>Sanna Hannukainen</last_name>
      <phone>00358505220271</phone>
      <email>sanna.hannukainen@terveystalo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Markku Nissilä, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nina Suvanto-Collán, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 20, 2016</lastchanged_date>
  <firstreceived_date>December 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Aura</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
